<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20060312152539+01'00'</creation_date><modification_date>D:20071011112020+02'00'</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-99-100_h_dec_1.pdf</pdf_file></head><body><section><header>i commission of the european communities  
  
  
  
  
  
 brussels,   15/09/1999 
  
  
  
 c(1999)  3012</header></section><section><header>not for publication          commission decision</header><p>of 15/09/1999</p><p>amending the marketing authorization for the</p><p>
 medicinal product for human use</p></section><section><header>&quot;cetrotide - cetrorelix (as acetate)&quot;</header><p>only the german text is authentic</p><p> ii</p></section><section><header>commission decision</header><p>of 15/09/1999</p><p>amending the marketing authorization for the</p><p>
 medicinal product for human use</p></section><section><header>&quot;cetrotide - cetrorelix (as acetate)&quot;</header><p>only the german text is authentic</p><p>the commission of the european communities,</p><p>
 having regard to the treaty establishing the european community,</p><p>
 having regard to council regulation (eec) no 2309/93 of 22 july 1993 laying down 
 community procedures for the authorization and supervision of medicinal products for 
 human and veterinary use and establishing a european agency for the evaluation of 
 medicinal products,
 1 as amended by commission regulation (ec) no 649/98,2</p><p>having regard to council directive 92/27/eec of 31 march 1992 on the labelling of medicinal products for human use and on package leaflets,
 3 and in particular article 10(3) thereof,</p><p>
 having regard to the request to change the package leaflet concerning the medicinal product 
 &quot;cetrotide - cetrorelix (as acetate)&quot;</p><p>entered in the community register of medicinal products under nos: eu/1/99/100/001-003, submitted on 19 may 1999 pursuant to 
 article 10(3) of the abovementioned council directive,</p><p>
 whereas the proposed changes are not connected with the contents of the summary of 
 characteristics of the medicinal product in question;</p><p>
 whereas, moreover, the package leaflet as changed continue to comply with the 
 requirements of directive 92/27/eec,</p><p>
 whereas decision c(1999) 939 of 13 april 1999 authorising the placing on the market of 
 the medicinal product 
 &quot;cetrotide - cetrorelix (as acetate)&quot; should therefore be amended,</p><p>
 1</p><p>oj no l 214, 24. 8. 1993, p. 1. 2</p><p>oj no l 88, 24.3.1998, p. 7. 3</p><p>oj l 113, 30.04.1992, p. 8.</p><p>iii 
 has adopted this decision:</p><p>
 article 1</p><p>
 decision c(1999) 939 is hereby amended as follows:</p><p>
 annex iii b (package leaflet) is replaced by annex i to this decision.</p><p>
 article 2</p><p>
 this decision is addressed to 
 asta medica aktiengesellschaft, an der pikardie 10, 01227 dresden, deutschland.</p><p> done at brussels, 15/09/1999</p><p>for the commission</p><p>
 karel van miert</p><p>
 member 
 of 
 the 
 commission</p></section></body></xml>